Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: incretin


Metformin improves blood glucose by increasing incretins independent of changes in gluconeogenesis in youth with type 2 diabetes

September 7th 2020

Overall, the improved postprandial blood glucose levels and increase in incretins observed in the absence of changes in insulin sensitivity and gluconeogenesis, support an enteroinsular mechanistic pathway in youth with type 2 diabetes treated with short-term metformin (Diabetologia)

Categories: Medication, News
Tags: incretin, metformin, Type 2 Diabetes

Categories: Medication
Tags: incretin, metformin, Type 2 Diabetes

The effects of incretin‐based therapies on beta‐cell function and insulin resistance in type 2 diabetes: a systematic review and network meta‐analysis combining 360 trials

December 13th 2018

Incretin‐based therapies not only show an increase of HOMA‐β and fasting C‐Peptide level, but also achieve a reduction of HOMA‐IR and FPG in comparison with placebo. Even though GRADE evidences indicate low to moderate for most comparisons, incretin‐based therapies seem to be advisable option for long term treatment to obtain preservation of β‐cell function (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: incretin, Type 2 Diabetes

Categories: Medication
Tags: incretin, Type 2 Diabetes

Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti‐hyperglycaemic drugs, when added to metformin

October 11th 2018

Real world evidence in people with Type 2 diabetes (Diabetic Medicine)

Categories: Medication, News
Tags: incretin, pancreatic, Type 2 Diabetes

Categories: Medication
Tags: incretin, pancreatic, Type 2 Diabetes

Sodium-Glucose Cotransporter-2 Inhibition Improves Incretin Sensitivity of Pancreatic β-cells in Patients with Type 2 Diabetes

August 8th 2017

Dapagliflozin improved β-cell responses to incretin hormones as well as glucose during the hyperglycemic clamp in patients with inadequately controlled T2DM (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: beta cells, incretin, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: beta cells, incretin, SGLT2 inhibitors, Type 2 Diabetes

Efficacy and safety of incretin-based drugs in patients with type 1 diabetes mellitus: A systematic review and meta-analysis

June 1st 2017

Incretin-based treatment in patients with T1DM may improve glycemic control and reduce insulin dose and weight without increasing the risk of serious adverse event, such as severe hypoglycemia, ketosis or ketoacidosis (Diabetes Research and Clinical Practice)

Categories: Medication, News
Tags: incretin, Type 1 Diabetes

Categories: Medication
Tags: incretin, Type 1 Diabetes

Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect

May 31st 2017

Prediabetes was highly prevalent in women with pGDM, and alterations in the incretin effect were detected in this group before the development of type 2 diabetes (diabetologia)

Categories: Gestational, News
Tags: incretin, prediabetes

Categories: Gestational
Tags: incretin, prediabetes

Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis

August 2nd 2016

In this large population-based study, use of incretin-based drugs was not associated with an increased risk of acute pancreatitis compared with other oral antidiabetic drugs (JAMA Internal Medicine)

Categories: Medication, News
Tags: incretin, pancreatitis

Categories: Medication
Tags: incretin, pancreatitis

Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus

August 2nd 2016

The use of GLP-1 analogues was associated with an increased ri sk of bile duct and gallbladder disease. Physicians should be aware of this potential adverse event when prescribing these drugs (JAMA Internal Medicine)

Categories: Medication, News
Tags: bile duct, gallbladder, incretin, Type 2 Diabetes

Categories: Medication
Tags: bile duct, gallbladder, incretin, Type 2 Diabetes

The Safety of Dipeptidyl Peptidase 4 Inhibitors and the Risk for Heart Failure

April 14th 2016

Owing to the well-documented microvascular benefit of improved glycemic control, the identification of cardiovascular-safe diabetes drugs that effectively lower glucose remains an important clinical need. The incretin therapies thus fulfill this goal. Ultimately, we need diabetes drugs that also reduce cardiovascular risk, and that will only be demonstrated through a continued commitment to long-term outcome studies (JAMA Cardiology)

Categories: Medication, News
Tags: DPP4 inhibitors, incretin

Categories: Medication
Tags: DPP4 inhibitors, incretin

Impact of Metformin on Metastases in Patients with Breast Cancer and Type 2 Diabetes

April 12th 2016

The use of metformin and incretins in women with T2DM and BC may reduce the risk of metastases (Journal of Diabetes and Its Complications)

Categories: Medication, News
Tags: breast cancer, incretin, metformin, Type 2 Diabetes

Categories: Medication
Tags: breast cancer, incretin, metformin, Type 2 Diabetes

A Multicenter Observational Study of Incretin-based Drugs and Heart Failure

April 9th 2016

In this analysis of data from large cohorts of patients with diabetes, incretin-based drugs were not associated with an increased risk of hospitalization for heart failure, as compared with commonly used combinations of oral antidiabetic drugs (NEJM)

Categories: Medication, News
Tags: incretin

Categories: Medication
Tags: incretin

Incretin-Based Therapy for Prevention of Diabetic Vascular Complications

December 31st 2015

The present review will summarize the relationship between multiple adverse biological mechanisms in diabetes and putative incretin-based therapeutic interventions intended to prevent diabetic vascular complications (Journal of Diabetes Research)

Categories: News, Treatment
Tags: incretin, vascular complications

Categories: Treatment
Tags: incretin, vascular complications

Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to insulin degludec/liraglutide

November 3rd 2015

Although the effects differ with each individual class of therapy, clinical trials have shown that adding a glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor or sodium-glucose co-transporter-2 inhibitor to insulin regimens can offer a significant reduction in HbA1c without substantially increasing hypoglycaemia risk, or weight (Diabetic Medicine)

Categories: Medication, News
Tags: incretin, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: incretin, SGLT2 inhibitors, Type 2 Diabetes

Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes

October 12th 2015

In patients on background incretin mimetics, canagliflozin improved HbA1c, body weight and BP, with an increased incidence of AEs related to SGLT2 inhibition (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: canagliflozin, incretin, SGLT2

Categories: Medication
Tags: canagliflozin, incretin, SGLT2

Investigating incretin-based therapies as a novel treatment for depression in type 2 diabetes: Findings from the South London Diabetes (SOUL-D) Study

July 7th 2015

The incretin group experienced significant reduction in depressive symptoms compared to controls. This was independent of HbA1c and may be mediated by an anti-inflammatory mechanism (Primary Care Diabetes)

Categories: News, Psychological
Tags: incretin

Categories: Psychological
Tags: incretin

Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young

May 27th 2015

The pathophysiology of HNF1A-diabetes includes exaggerated postprandial glucagon responses and increased fasting DPP-4 enzymatic activity, but normal postprandial incretin responses in both patients with GCK-diabetes and HNF1A-diabetes (European Journal of Endocrinology)

Categories: News, Pathology
Tags: DPP4, incretin, MODY

Categories: Pathology
Tags: DPP4, incretin, MODY

Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study

January 31st 2015

Our findings suggest that the use of incretin-based drugs appears not to be associated with an increased risk of acute pancreatitis (Diabetes Care)

Categories: Medication, News
Tags: incretin, pancreatitis

Categories: Medication
Tags: incretin, pancreatitis

Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients

January 6th 2015

Disordered early phase insulin and glucagon secretions but not incretin secretion are involved in hyperglycemia after ingestion of nutrients in T2DM of even a short duration (Journal of Diabetes and Its Complications)

Categories: Biochemistry, Diet, News
Tags: glucagon, hyperglycemia, incretin, insulin, Type 2 Diabetes

Categories: Biochemistry, Diet
Tags: glucagon, hyperglycemia, incretin, insulin, Type 2 Diabetes

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

Novo NordiskBoehringer IngelheimAstraZenecaNapp Diabetes

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes CareAbout Ascensia Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 DPP4 inhibitors Empagliflozin exenatide GLP-1 RA GLP-1RA GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership